Your browser doesn't support javascript.
loading
High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.
Kawabata, K C; Hayashi, Y; Inoue, D; Meguro, H; Sakurai, H; Fukuyama, T; Tanaka, Y; Asada, S; Fukushima, T; Nagase, R; Takeda, R; Harada, Y; Kitaura, J; Goyama, S; Harada, H; Aburatani, H; Kitamura, T.
Afiliação
  • Kawabata KC; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Hayashi Y; Division of Hematology/Medical Oncology, Department of Medicine, Weill-Cornell Medical College, Cornell University, New York, NY, USA.
  • Inoue D; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Meguro H; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Sakurai H; Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fukuyama T; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.
  • Tanaka Y; Division of Hematology, Department of Medicine, Juntendo University, Bunkyo, Japan.
  • Asada S; Division of Hemalogy, Shizuoka Hospital, Juntendo University, Izunokuni, Japan.
  • Fukushima T; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Nagase R; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Takeda R; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Harada Y; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Kitaura J; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Goyama S; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
  • Harada H; Division of Hematology, Department of Medicine, Juntendo University, Bunkyo, Japan.
  • Aburatani H; Department of Clinical Laboratory Medicine, Faculty of Health Science Technology, Bunkyo Gakuin University, Bunkyo, Japan.
  • Kitamura T; Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
Leukemia ; 32(2): 419-428, 2018 02.
Article em En | MEDLINE | ID: mdl-28720764
ABSTRACT
Both proto-oncogenic and tumor-suppressive functions have been reported for enhancer of zeste homolog 2 (EZH2). To investigate the effects of its inactivation, a mutant EZH2 lacking its catalytic domain was prepared (EZH2-dSET). In a mouse bone marrow transplant model, EZH2-dSET expression in bone marrow cells induced a myelodysplastic syndrome (MDS)-like disease in transplanted mice. Analysis of these mice identified Abcg2 as a direct target of EZH2. Intriguingly, Abcg2 expression alone induced the same disease in the transplanted mice, where stemness genes were enriched. Interestingly, ABCG2 expression is specifically high in MDS patients. The present results indicate that ABCG2 de-repression induced by EZH2 mutations have crucial roles in MDS pathogenesis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína Potenciadora do Homólogo 2 de Zeste / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína Potenciadora do Homólogo 2 de Zeste / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article